{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:37:19Z","timestamp":1768354639986,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"DOI":"10.7759\/cureus.28372","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:12:57Z","timestamp":1661418777000},"source":"Crossref","is-referenced-by-count":2,"title":["Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma"],"prefix":"10.7759","author":[{"given":"Mercedes","family":"Molero-Senosiain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Liseth","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Benito-Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Valor-Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long GV","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al.. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017, 377:1813-23. 10.1056\/NEJMoa1708539","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0541-0","article-title":"Ocular toxicity due to trametinib and dabrafenib","volume":"17","author":"Sarny S","year":"2017","unstructured":"Sarny S, Neumayer M, Kofler J, El-Shabrawi Y. Ocular toxicity due to trametinib and dabrafenib. BMC Ophthalmol. 2017, 17:146. 10.1186\/s12886-017-0541-0","journal-title":"BMC Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher AW","year":"2015","unstructured":"Tolcher AW, Patnaik A, Papadopoulos KP, et al.. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol. 2015, 75:183-9. 10.1007\/s00280-014-2615-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard O","year":"2014","unstructured":"Huillard O, Bakalian S, Levy C, et al.. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer. 2014, 50:638-48. 10.1016\/j.ejca.2013.10.016","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy GK","year":"2013","unstructured":"Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013, 63:249-79. 10.3322\/caac.21184","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2018.01.008","article-title":"Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib","volume":"93","author":"Rueda-Rueda T","year":"2018","unstructured":"Rueda-Rueda T, S\u00e1nchez-Vicente JL, Moruno-Rodr\u00edguez A, Molina-Socola FE, Mart\u00ednez-Borrego AC, L\u00f3pez-Herrero F. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol (Engl Ed). 2018, 93:458-62. 10.1016\/j.oftal.2018.01.008","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000585","article-title":"Bilateral visual field defects in a patient treated with the MEK and BRAF inhibitors trametinib and dabrafenib for melanoma of unknown origin","volume":"13","author":"Siedlecki J","year":"2019","unstructured":"Siedlecki J, Mackert M, Wolf A, Berking C, Priglinger SG, Eibl-Lindner K. Bilateral visual field defects in a patient treated with the MEK and BRAF inhibitors trametinib and dabrafenib for melanoma of unknown origin. Retin Cases Brief Rep. 2019, 13:215-9. 10.1097\/ICB.0000000000000585","journal-title":"Retin Cases Brief Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1261166","article-title":"Bilateral ischemic retinal vasculitis in metastatic cutaneous melanoma patient treated with dabrafenib and trametinib: a case report","volume":"26","author":"Niro A","year":"2018","unstructured":"Niro A, Recchimurzo N, Sborgia A, Guida M, Alessio G. Bilateral ischemic retinal vasculitis in metastatic cutaneous melanoma patient treated with dabrafenib and trametinib: a case report. Ocul Immunol Inflamm. 2018, 26:783-5. 10.1080\/09273948.2016.1261166","journal-title":"Ocul Immunol Inflamm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1246-0","article-title":"Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study","volume":"15","author":"de la Cruz-Merino L","year":"2017","unstructured":"de la Cruz-Merino L, Di Guardo L, Grob JJ, et al.. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017, 15:146. 10.1186\/s12967-017-1246-0","journal-title":"J Transl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00267","article-title":"Scrambling for BRAF mutation status in patients with melanoma: is it really necessary to initiate treatment?","volume":"1","author":"Farooq MZ","year":"2022","unstructured":"Farooq MZ, Mangla A. Scrambling for BRAF mutation status in patients with melanoma: is it really necessary to initiate treatment?. JCO Oncol Pract. 2022, 1:OP2200267. 10.1200\/OP.22.00267","journal-title":"JCO Oncol Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial\u2014ECOGACRIN EA6134","volume":"39","author":"Atkins MB","year":"2021","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al.. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial\u2014ECOGACRIN EA6134. J Clin Oncol. 2021, 39:356154. 10.1200\/JCO.2021.39.36_suppl.356154","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/106489-retinal-vein-occlusion-in-a-patient-on-dabrafenib-and-trametinib-therapy-for-metastatic-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:50:34Z","timestamp":1707508234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/106489-retinal-vein-occlusion-in-a-patient-on-dabrafenib-and-trametinib-therapy-for-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.28372","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}